CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 20 enrolled
Drug / intervention
Atomoxetine +1 moredrug
Likely dose
Atomoxetine 20 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01557569
NCT01557569Phase 2Completed
CompareCT.gov

Clinical Efficacy of Atomoxetine for Methamphetamine Dependence

University of Arkansas·interventional·Posted Mar 19, 2012·Updated Feb 9, 2017

In Brief

A Phase 2 clinical trial evaluating Atomoxetine and placebo for Methamphetamine Dependence. Completed, enrolled 20 participants across 1 site.

Detailed Summary

The purpose of this study is to examine the ability of atomoxetine compared to placebo to increase time to relapse in methamphetamine dependent volunteers. Our hypothesis is that atomoxetine will increase time before (if) the participant relapses.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMethamphetamine Dependence
CountriesUnited States
CollaboratorsNational Institute on Drug Abuse (NIDA)

Timeline

Phase 2CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedMar 19, 2012
Enrollment StartApr 1, 2012
Primary CompletionJun 1, 2015
Study CompletionJul 1, 2015
TodayJul 2, 2026
Enrollment to primary: 3.2 yearsPosted 14.3 years ago

Interventions

Atomoxetinedrug

During the first 2 weeks and three days the dose of atomoxetine will be titrated up starting with 20 mg/day for first 3 days, 36 mg/day for next 4 days, 50 mg/day for next 3 days, and finally 80 mg/day until the final day of the study (week 10, day 7)

placebodrug

participants in this group will receive 1 dose of placebo daily for the entire 10-weeks.